Search Result

Results for "

hyperactivity

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (9) Adrenergic Receptor (12) Amyloid-β (1) Angiotensin Receptor (1) Apoptosis (2) Autophagy (2) Biochemical Assay Reagents (1) c-Fms (1) Calcium Channel (1) Caspase (2) COX (2) Dopamine Receptor (5) Dopamine Transporter (1) Drug Metabolite (1) Endogenous Metabolite (1) Estrogen Receptor/ERR (1) GABA Receptor (1) GPR52 (1) HDAC (1) Histamine Receptor (6) iGluR (1) Interleukin Related (2) Isotope-Labeled Compounds (2) mGluR (3) Mitophagy (2) Monoamine Transporter (4) nAChR (5) NF-κB (1) p38 MAPK (3) PGE synthase (2) Phosphodiesterase (PDE) (3) PPAR (1) Serotonin Transporter (4) Sigma Receptor (2) Sodium Channel (5)
By Research Areas:	Cancer (9) Cardiovascular Disease (5) Endocrinology (10) Inflammation/Immunology (4) Neurological Disease (50)
Oligonucleotides:	Antisense Oligonucleotides (2)

Inhibitors & Agonists

Fluorescent Dye

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-156532

5-HT2C agonist-3	5-HT Receptor	Neurological Disease
5-HT2C agonist-3 ((+)-19) is a selective 5-HT2C agonist (EC₅₀: 24 nM, K_i: 78 nM). 5-HT2C agonist-3 has antipsychotic drug-like activity. 5-HT2C agonist-3 blocks Amphetamine-induced hyperactivity .

HY-14880B

Bavisant dihydrochloride hydrate JNJ31001074AAC; JNJ31001074 dihydrochloride hydrate	Histamine Receptor	Neurological Disease Endocrinology
Bavisant dihydrochloride hydrate (JNJ31001074AAC) is an orally active, potent, brain-penetrating and highly selective antagonist of the histamine H₃ receptor. Bavisant dihydrochloride hydrate can be used for attention-deficit hyperactivity disorder (ADHD) research .

HY-14880

Bavisant JNJ-31001074	Histamine Receptor	Neurological Disease Endocrinology
Bavisant (JNJ-31001074) is an orally active, potent, brain-penetrating and highly selective antagonist of the histamine H₃ receptor. Bavisant can be used for attention-deficit hyperactivity disorder (ADHD) research .

HY-120076

CP-293019	Dopamine Receptor	Neurological Disease
CP-293019 is a dopamine D4 receptor antagonist, with a K_i value of 3.4 nM. CP-293019 can inhibit Apomorphine (HY-12723) induced hyperactivity in rats .

HY-B1495

Quipazine maleate	5-HT Receptor	Neurological Disease
Quipazine maleate is a 5-HT agonist that causes behavioural changes such as hyperactivity. Quipazine maleate also shows a weak reversible MAO inhibitory activity .

HY-108346

JX401	p38 MAPK	Inflammation/Immunology
JX401 is a potent inhibitor of p38alpha, containing a 4-benzylpiperidine motif. p38alpha is hyperactive in inflammatory diseases, and various indications suggest that its inhibition would reverse inflammation. JX401 has the potential for the research of inflammation .

HY-109149

Lomardexamfetamine KP 106	Others	Neurological Disease
Lomardexamfetamine (KP 106) is an orally active central nervous system stimulant composed of d-amphetamine and a ligand. Lomardexamfetamine can be used for the research of attention-deficit hyperactivity disorder .

HY-156532A

5-HT2C agonist-3 free base	5-HT Receptor	Neurological Disease
5-HT2C agonist-3 ((+)-19) free base is a selective 5-HT2C agonist (EC₅₀: 24 nM, K_i: 78 nM). 5-HT2C agonist-3 free base has antipsychotic drug-like activity. 5-HT2C agonist-3 free base blocks Amphetamine-induced hyperactivity .

HY-14880A

Bavisant dihydrochloride JNJ-31001074 dihydrochloride	Histamine Receptor	Neurological Disease Endocrinology
Bavisant (JNJ-31001074) dihydrochloride is an orally active, potent, brain-penetrating and highly selective antagonist of the histamine H₃ receptor. Bavisant dihydrochloride can be used for attention-deficit hyperactivity disorder (ADHD) research .

HY-147529

mGluR2 modulator 3	mGluR	Neurological Disease
mGluR2 modulator 3 (compound 1) is a potent mGluR2 positive allosteric modulator with an EC₅₀ value of 0.87 μM. mGluR2 modulator 3 has activity in psychosis disease models such as methamphetamine-induced hyperactivity and mescaline-induced scratching in mice .

HY-107481

Fasoracetam NS 105	mGluR	Neurological Disease
Fasoracetam (NS 105) is the activator of metabotropic glutamate receptor (mGluR). Fasoracetam (NS 105) has the potential for the research of attention-deficit hyperactivity disorder (ADHD) and Alzheimer's disease (AD) .

HY-120741

PF-04822163	Phosphodiesterase (PDE)	Neurological Disease
PF-04822163 is an orally active, selective, and blood-brain barrier permeable PDE1 inhibitor with IC₅₀ values of 2 nM, 2.4 nM, and 7 nM for PDE1A, PDE1B, and PDE1C respectively. PF-04822163 can be used in the research of attention deficit hyperactivity disorder or Parkinson's disease .

HY-139897

CX 717	iGluR	Neurological Disease
CX 717 is a positive allosteric modulator of AMPA receptor. Antidepressant-like effect. CX 717 can be used for the research of adult attention deficit hyperactivity disorder (ADHD) .

HY-P99031

Mavrilimumab CAM 3001	c-Fms	Cardiovascular Disease Inflammation/Immunology
Mavrilimumab (CAM 3001) is a monoclonal antibody that binds to the α subunit of the granulocyte-macrophage colony stimulating factor (GM-CSF) receptor and blocks intracellular signalling downstream of GM-CSF. GM-CSF might be a mediator of the hyperactive inflammatory response associated with respiratory failure and death .

HY-121313

Embusartan BAY 10-6734	Angiotensin Receptor	Neurological Disease Endocrinology
Embusartan (BAY 10-6734) is a brain-penetrant and effective AT1 receptor blocker. Embusartan inhibits Ang II binding to brain AT1 receptors in the nuclei of central nervous system (CNS) inside due to high lipophilic character. Embusartan is promising for research of sympathetic hyperactivity and hypertension .

HY-106993

Cipralisant GT-2331	Histamine Receptor	Neurological Disease Endocrinology
Cipralisant (GT-2331) is an orally active, low-toxicity, potent, selective, high affinity histamine H3 receptor full antagonist in vivo, and an agonist in vitro, with a pK_i of 9.9 for histamine H3 receptor and a K_i of 0.47 nM for rat histamine H3 receptor. Cipralisant has the potential for attention-deficit hyperactivity disorder research . Cipralisant is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-106993A

Cipralisant maleate GT-2331 maleate	Histamine Receptor	Neurological Disease
Cipralisant (GT-2331) (maleate) is an orally active, low-toxicity, potent, selective, high affinity histamine H3 receptor full antagonist in vivo, and an agonist in vitro, with a pK_i of 9.9 for histamine H3 receptor and a K_i of 0.47 nM for rat histamine H3 receptor. Cipralisant (maleate) has the potential for attention-deficit hyperactivity disorder research . Cipralisant (maleate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-147395

GPR52 agonist-1	GPR52	Neurological Disease
GPR52 agonist-1 is a potent, orally active and blood-brain barrier (BBB) penetrant GPR52 agonist with an pEC₅₀ value of 7.53. GPR52 agonist-1 affects cAMP accumulation through direct interaction with GPR52. GPR52 agonist-1 can significantly suppress Methamphetamine-induced hyperactivity in mice. Antipsychotic activity .

HY-15543A

CP-809101 hydrochloride 1 Publications Verification	5-HT Receptor	Neurological Disease
CP-809101 hydrochloride is a potent and highly selective 5-HT_2C receptor agonist, with pEC₅₀s of 9.96, 7.19 and 6.81 M for human 5HT_2C, 5HT_2B and 5HT_2A receptor. CP-809101 hydrochloride inhibits conditioned avoidance responding in rats and antagonizes both PCP (phencyclidine hydrochloride)- and d-amphetamine-induced hyperactivity. CP-809101 hydrochloride also reduces food and nicotine dependence in rats, can be used in studies of antipsychotic and nicotine dependence .

HY-15543

CP-809101	5-HT Receptor	Neurological Disease
CP-809101 is a potent and highly selective 5-HT_2C receptor agonist, with pEC₅₀s of 9.96, 7.19 and 6.81 M for human 5HT_2C, 5HT_2B and 5HT_2A receptor. CP-809101 inhibits conditioned avoidance responding in rats and antagonizes both PCP (phencyclidine hydrochloride)- and d-amphetamine-induced hyperactivity. CP-809101 also reduces food and nicotine dependence in rats, can be used in studies of antipsychotic and nicotine dependence .

HY-17416A

Guanfacine	Adrenergic Receptor	Neurological Disease Endocrinology
Guanfacine is an orally active noradrenergic α2A agonist and has high selective for the α2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD) .

HY-17416

Guanfacine hydrochloride 2 Publications Verification	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Guanfacine hydrochloride is an orally active noradrenergic α2A agonist and has high selective for the α2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD) .

HY-B1081

Oxidopamine hydrochloride Maximum Cited Publications 17 Publications Verification 6-Hydroxydopamine Hydrochloride	Dopamine Receptor Autophagy Mitophagy COX PGE synthase Interleukin Related p38 MAPK Apoptosis Caspase	Neurological Disease Cancer
Oxidopamine (6-OHDA) hydrochloride is an antagonist of the neurotransmitter dopamine. Oxidopamine hydrochloride is a widely used neurotoxin and selectively destroys dopaminergic neurons. Oxidopamine hydrochloride promotes COX-2 activation, leading to PGE₂ synthesis and pro-inflammatory cytokine IL-1β secretion. Oxidopamine hydrochloride can be used for the research of Parkinson’s disease (PD), attention-deficit hyperactivity disorder (ADHD), and Lesch-Nyhan syndrome .

HY-B1081A

Oxidopamine hydrobromide Maximum Cited Publications 17 Publications Verification 6-Hydroxydopamine hydrobromide; 6-OHDA hydrobromide	Dopamine Receptor Autophagy Mitophagy COX PGE synthase Interleukin Related p38 MAPK Apoptosis Caspase	Neurological Disease Cancer
Oxidopamine (6-OHDA) hydrobromide is an antagonist of the neurotransmitter dopamine. Oxidopamine hydrobromide is a widely used neurotoxin and selectively destroys dopaminergic neurons. Oxidopamine hydrobromide promotes COX-2 activation, leading to PGE₂ synthesis and pro-inflammatory cytokine IL-1β secretion. Oxidopamine hydrobromide can be used for the research of Parkinson’s disease (PD), attention-deficit hyperactivity disorder (ADHD), and Lesch-Nyhan syndrome .

HY-17416R

Guanfacine hydrochloride (Standard)	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Guanfacine (hydrochloride) (Standard) is the analytical standard of Guanfacine (hydrochloride). This product is intended for research and analytical applications. Guanfacine hydrochloride is an orally active noradrenergic α2A agonist and has high selective for the α2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD) .

HY-17416AS1

Guanfacine-15N3,13C2	Adrenergic Receptor Isotope-Labeled Compounds	Neurological Disease Endocrinology
Guanfacine- ¹⁵N₃, ¹³C₂ is ¹⁵N and ¹³C labeled Guanfacine (HY-17416A). Guanfacine is an orally active noradrenergic α2A agonist and has high selective for the α2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD) .

HY-15413A

Edivoxetine hydrochloride LY 2216684 hydrochloride	Serotonin Transporter	Neurological Disease
Edivoxetine (hydrochloride) is a selective and potent norepinephrine reuptake inhibitor (NERI) being used in depressive disorder or attention-deficit/hyperactivity disorder.

HY-15413

Edivoxetine LY 2216684	Adrenergic Receptor	Neurological Disease
Edivoxetine is a selective and potent norepinephrine reuptake inhibitor (NERI) being used in depressive disorder or attention-deficit/hyperactivity disorder.

HY-W042214

Ritalinic acid Ritalinate	Drug Metabolite	Others
Ritalinic acid (Ritalinate) is the main inactive urinary metabolite of Methylphenidate. Methylphenidate has the potential for attention-deficit hyperactivity disorder and narcolepsy research .

HY-19845

Ordopidine ACR-325	Dopamine Receptor	Neurological Disease
Ordopidine is a dopamine D2 receptor antagonist. Ordopidine can inhibit hyperactivity caused by psychostimulants. Ordopidine can be used in neurological research .

HY-14824

Sofiniclin ABT 894	nAChR	Neurological Disease
Sofiniclin (ABT 894), an agonist of nicotinic acetylcholine receptor (nAChR), is used as a potential non-stimulant research for attention-deficit/hyperactivity disorder (ADHD) .

HY-139786

Cofirasersen ION-827359	Sodium Channel	Others
Cofirasersen is designed to reduce the expression of ENaC in the lung. ENaC is a sodium transport channel and believed to be hyperactive in cystic fibrosis, which is caused by mutations in the cystic fibrosis transmembrane regulator gene.

HY-139786A

Cofirasersen sodium ION-827359 sodium	Sodium Channel	Others
Cofirasersen sodium is designed to reduce the expression of ENaC in the lung. ENaC is a sodium transport channel and believed to be hyperactive in cystic fibrosis, which is caused by mutations in the cystic fibrosis transmembrane regulator gene.

HY-101248

GR-46611	5-HT Receptor	Cancer
GR-46611 is a 5-HT_1D receptor agonist. GR-46611 can be used in the research of bladder hyperactivity, leukemia .

HY-B0590

Tetrabenazine Ro 1-9569	Monoamine Transporter	Neurological Disease
Tetrabenazine (Ro 1-9569) is a reversible inhibitor of the vesicular monoamine transporter VMAT2 with the K_d value of 1.34 nM. Tetrabenazine can be used for research on diseases related to hyperactive movement disorders such as Huntington's disease .

HY-B0590E

Tetrabenazine mesylate Ro 1-9569 mesylate	Monoamine Transporter	Neurological Disease
Tetrabenazine (Ro 1-9569) mesylate is a reversible inhibitor of the vesicular monoamine transporter VMAT2 with the K_d value of 1.34 nM. Tetrabenazine mesylate can be used for research on diseases related to hyperactive movement disorders such as Huntington's disease .

HY-128420

Lobeline sulfate α-Lobeline sulfate; L-Lobeline sulfate	nAChR Dopamine Transporter	Neurological Disease
Lobeline (α-Lobeline) sulfate is a brain-penetrant nicotinic receptor agonist. Lobeline sulfate increases dopamine (DA) release by inhibiting DA uptake into synaptic vesicles, and altering presynaptic DA storage. Lobeline sulfate is effective in smoking cessation .

HY-N1990

Gypenoside XLIX	PPAR	Cardiovascular Disease Inflammation/Immunology
Gypenoside XLIX, a dammarane-type glycoside, is a prominent component of G. pentaphyllum. Gypenoside XLIX is a selective peroxisome proliferator-activated receptor (PPAR)-alpha activator and inhibits cytokine-induced vascular cell adhesion molecule-1 (VCAM-1) overexpression and hyperactivity in human endothelial cells .

HY-144070A

(Rac)-ErSO-DFP	Estrogen Receptor/ERR	Cancer
(Rac)-ErSO-DFP is a derivative of ErSO-DFP and a selective small molecule Erα biomodulator. (Rac)-ErSO-DFP againsts ERα+ breast cancer (including resistant tumors) by hyperactiving the Erα-dependent a-UPR (extracted from patent WO2022087234A1) .

HY-108512

PD 144418 1 Publications Verification	Sigma Receptor	Neurological Disease
PD 144418 is a highly affinity, potent and selective sigma 1 (σ1) receptor ligand (K_i values of 0.08 nM and 1377 nM for σ1 and σ2 respectively). PD 144418 devoids of any significant affinity for other receptors, ion channels and enzymes. PD 144418 shows potential antipsychotic activity .

HY-108512A

PD 144418 oxalate 1 Publications Verification	Sigma Receptor	Neurological Disease
PD 144418 oxalate is a highly affinity, potent and selective sigma 1 (σ1) receptor ligand (K_i values of 0.08 nM and 1377 nM for σ1 and σ2 respectively). PD 144418 oxalate devoids of any significant affinity for other receptors, ion channels and enzymes. PD 144418 oxalate shows potential antipsychotic activity .

HY-136569

DSR-141562	Phosphodiesterase (PDE)	Neurological Disease
DSR-141562 is a novel, orally active, and selective brain-penetrant phosphodiesterase 1 (PDE1) inhibitor. DSR-141562 shows preferential selectivity for human PDE1B with an IC₅₀ of 43.9 nM, and the IC₅₀ values for human PDE1A and 1C are 97.6 and 431.8 nM, respectively. DSR-141562 can be used for the study of positive symptoms, negative symptoms and cognitive impairments associated with schizophrenia .

HY-103155

SB-221284	5-HT Receptor	Neurological Disease
SB 221284 is a selective 5-HT_2C/2B receptor antagonist with pK_i values are 6.4, 7.9 and 8.6 for 5-HT_2A, 5-HT_2B and 5-HT_2C receptors, respectively. SB 221284 can be used for the research of neurological disease .

HY-B0590R

Tetrabenazine (Standard)	Monoamine Transporter	Neurological Disease
Tetrabenazine (Standard) is the analytical standard of Tetrabenazine. This product is intended for research and analytical applications. Tetrabenazine (Ro 1-9569) is a reversible inhibitor of the vesicular monoamine transporter VMAT2 with the K_d value of 1.34 nM. Tetrabenazine can be used for research on diseases related to hyperactive movement disorders such as Huntington's disease .

HY-17385

Atomoxetine hydrochloride 4 Publications Verification Tomoxetine hydrochloride; (R)-Tomoxetine hydrochloride; LY 139603	Adrenergic Receptor Serotonin Transporter Sodium Channel	Neurological Disease Cancer
Atomoxetine (Tomoxetine) hydrochloride is a selective noradrenaline reuptake inhibitor with K_i values of 5 nM, 77 nM and 1451 nM for norepinephrine (NE), serotonin (5-HT) and dopamine (DA) transporters, respectively. Atomoxetine hydrochloride is a potent Na ⁺ channels (VGSCs) blocker. Atomoxetine hydrochloride can be used for attention-deficit hyperactivity disorder (ADHD) research .

HY-13458A

Droxidopa hydrochloride L-DOPS hydrochloride; DOPS hydrochloride; SM5688 hydrochloride	Adrenergic Receptor	Neurological Disease
Droxidopa (L-DOPS) hydrochloride is a potent, orally active norepinephrine precursor. Droxidopa hydrochloride increases standing blood pressure, ameliorates symptoms of orthostatic hypotension and improves standing ability. Droxidopa hydrochloride has the potential for the research of neurogenic orthostatic hypotension (nOH) and alternative ADHD (attention deficit hyperactivity disorder) .

HY-110168

NS 9283	nAChR	Neurological Disease
NS9283 is a positive positive allosteric modulator of (α4)₃(β2)₂ nicotinic ACh receptors. NS9283 can be used in a series of neurological conditions such as attention deficit hyperactivity disorder (ADHD), schizophrenia, Parkinson's disease and Alzheimer's disease .

HY-13458

Droxidopa L-DOPS; DOPS; SM5688	Adrenergic Receptor	Neurological Disease
Droxidopa (L-DOPS; SM5688) is a potent, orally active norepinephrine precursor. Droxidopa increases standing blood pressure, ameliorates symptoms of orthostatic hypotension and improves standing ability. Droxidopa has the potential for the research of neurogenic orthostatic hypotension (nOH) and alternative ADHD (attention deficit hyperactivity disorder) .

HY-14824A

Sofinicline benzenesulfonate ABT 894 benzenesulfonate	nAChR	Neurological Disease
Sofinicline benzenesulfonate (ABT 894 benzenesulfonate) is a novel nicotinic acetylcholine receptor agonist, specifically acting on the α4β2 subtype of nAChR (IC₅₀=0.1 nM). Sofinicline benzenesulfonate has the potential to improve cognitive function, including attention, memory and working memory. Sofinicline benzenesulfonate can be used in studies of attention deficit, hyperactivity disorder (ADHD) .

HY-W206911

Erythrosin B sodium salt	Biochemical Assay Reagents	Others
Erythrosin B sodium salt, is a synthetic azo dye commonly used as a food colorant and textile dye. It is a water-soluble compound that produces a bright red color and is often used to improve the appearance of products. Erythrosin B sodium salt is also used in the textile industry for dyeing wool, silk and leather. However, it has been linked to potentially negative health effects, such as allergic reactions and hyperactivity in children.

Cat. No.	Product Name	Type

HY-W206911

Erythrosin B sodium salt

Dyes

Erythrosin B sodium salt, is a synthetic azo dye commonly used as a food colorant and textile dye. It is a water-soluble compound that produces a bright red color and is often used to improve the appearance of products. Erythrosin B sodium salt is also used in the textile industry for dyeing wool, silk and leather. However, it has been linked to potentially negative health effects, such as allergic reactions and hyperactivity in children.

HY-D0939

Direct Blue 1 Chicago Sky Blue 6B	Dyes
Direct Blue 1 (Chicago Sky Blue 6B) is a complex dye for background autofluorescence in immunofluorescence histochemistry. Direct Blue 1 is a potent and competitive VGLUT inhibitor. Direct Blue 1 can inhibit the Aβ-binding small molecule PrP ligand. Direct Blue 1 has anti-inflammatory activity .

Cat. No.	Product Name	Target	Research Area

HY-P99031

Mavrilimumab CAM 3001	c-Fms	Cardiovascular Disease Inflammation/Immunology
Mavrilimumab (CAM 3001) is a monoclonal antibody that binds to the α subunit of the granulocyte-macrophage colony stimulating factor (GM-CSF) receptor and blocks intracellular signalling downstream of GM-CSF. GM-CSF might be a mediator of the hyperactive inflammatory response associated with respiratory failure and death .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N1990

Gypenoside XLIX	Cardiovascular Disease Triterpenes Structural Classification Classification of Application Fields Terpenoids Source classification Cucurbitaceae Plants Gynostemma pentaphyllum (Thunb.) Makino Disease Research Fields	PPAR
Gypenoside XLIX, a dammarane-type glycoside, is a prominent component of G. pentaphyllum. Gypenoside XLIX is a selective peroxisome proliferator-activated receptor (PPAR)-alpha activator and inhibits cytokine-induced vascular cell adhesion molecule-1 (VCAM-1) overexpression and hyperactivity in human endothelial cells .

HY-128420

Lobeline sulfate α-Lobeline sulfate; L-Lobeline sulfate	Alkaloids Structural Classification other families Source classification Pyridine Alkaloids Plants Endogenous metabolite	nAChR Dopamine Transporter
Lobeline (α-Lobeline) sulfate is a brain-penetrant nicotinic receptor agonist. Lobeline sulfate increases dopamine (DA) release by inhibiting DA uptake into synaptic vesicles, and altering presynaptic DA storage. Lobeline sulfate is effective in smoking cessation .

HY-B2167R

Docosahexaenoic acid (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Source classification Disease markers Endogenous metabolite Cardiovascular System Disorder	Endogenous Metabolite
Docosahexaenoic acid (Standard) is the analytical standard of Docosahexaenoic acid. This product is intended for research and analytical applications. Docosahexaenoic Acid (DHA) is an omega-3 fatty acid abundantly present brain and retina. It can be obtained directly from fish oil and maternal milk. In Vitro: Docosahexaenoic acid (DHA) is essential for the growth and functional development of the brain in infants. DHA is also required for maintenance of normal brain function in adults. The inclusion of plentiful DHA in the diet improves learning ability and memory . DHA is an essential requirement in every step of brain development like neural cell proliferation, migration, differentiation, synaptogenesis. The multiple double bonds and unique structure allow DHA to impart special membrane characteristics for effective cell signaling. Many development disorders like dyslexia, autism spectrum disorder, attention deficit hyperactivity disorder, schizophrenia etc. are causally related to decreased level of DHA . DHA is a potent RXR ligand inducing robust RXR activation already at low micro molar concentrations. The EC₅₀ for RXRα activation by DHA is about 5-10 μM fatty acid . In Vivo: Docosahexaenoic acid administration over 10 weeks significantly reduces the number of reference memory errors, without affecting the number of working memory errors, and significantly increases the docosahexaenoic acid content and the docosahexaenoic acid/arachidonic acid ratio in both the hippocampus and the cerebral cortex . DHA treatment exerts neuroprotective actions on an experimental mouse model of PD. There is a decrease tendency in brain lipid oxidation of MPTP mice but it does not significantly .

Cat. No.	Product Name	Chemical Structure

HY-17416AS1

Guanfacine-15N3,13C2

Guanfacine- ¹⁵N₃, ¹³C₂ is ¹⁵N and ¹³C labeled Guanfacine (HY-17416A). Guanfacine is an orally active noradrenergic α2A agonist and has high selective for the α2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD) .

HY-17416AS

Guanfacine-13C,15N3

Guanfacine- ¹³C, ¹⁵N₃ is the ¹³C and ¹⁵N labeled Guanfacine[1]. Guanfacine is an orally active noradrenergic α2A agonist and has high selective for the α2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD)[2][3][4].

HY-17416S2

Guanfacine-13C,d5 hydrochloride

Guanfacine- ¹³C,d₅ hydrochloride is the deuterium and ¹³C labeled Guanfacine hydrochloride (HY-17416). Guanfacine hydrochloride is an orally active noradrenergic α2A agonist and has high selective for the α2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD) .

Cat. No.	Product Name		Classification